Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
3 hedge funds and large institutions have $19.7K invested in Dermata Therapeutics Warrant in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1.66% more ownership
Funds ownership: 0.71% → 2.37% (+1.7%)
25% less funds holding
Funds holding: 4 → 3 (-1)
32% less capital invested
Capital invested by funds: $29.2K → $19.7K (-$9.45K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$420 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1 |
DRMAW Hedge Fund Activity: Q3 2024 in Review
3 institutional investors reported a position in Dermata Therapeutics Warrant (DRMAW) for Q3 2024, worth a combined $19.7K — down 32% from $29.2K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DRMAW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Warberg Asset Management, exiting entirely with an estimated $420 sold.
- 3 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q3 2024, down from 4 in Q2 2024.
- Funds reported $19.7K of Dermata Therapeutics Warrant stock for Q3 2024, down 32% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest Dermata Therapeutics Warrant seller in Q3 2024 was Warberg Asset Management, an estimated $420 sold.
Based on aggregated 13F filings for Q3 2024.